Terutroban

Terutroban
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Investigational;
Pharmacokinetic data
Elimination half-life	6–10 hours
Identifiers
	IUPAC name 3-((6R)-6-{[(4-Chlorophenyl)sulfonyl]amido}-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid;
CAS Number	165538-40-9 ; 609340-89-8 (sodium salt);
PubChem CID	9938840;
ChemSpider	8114465 ;
UNII	A6WX9391D8;
ECHA InfoCard	100.107.361
Chemical and physical data
Formula	C20H22ClNO4S
Molar mass	407.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C2=C(CC(CC2)NS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1)CCC(=O)O;
	InChI InChI=1S/C20H22ClNO4S/c1-13-2-3-14-12-16(6-9-19(14)18(13)10-11-20(23)24)22-27(25,26)17-7-4-15(21)5-8-17/h2-5,7-8,16,22H,6,9-12H2,1H3,(H,23,24)/t16-/m1/s1 ; Key:HWEOXFSBSQIWSY-MRXNPFEDSA-N ;
	(what is this?) (verify)

Terutroban is an antiplatelet agent developed by Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications.[1]

It has been tested in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack).[2] The study was prematurely stopped and it could not be determined whether terutroban has a better effect than aspirin. The 2011 clinical trial that studied the antiplatelet agent versus aspirin found that it was not superior in the prevention of cerebral and cardiovascular ischaemic events, although it was significantly better in patients who already suffered previous stroke to the qualifying event.[3]

Researchers from the University of Milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis.[4]

Method of action

Aside from its anti-inflammatory effect, terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane induced platelet aggregation and vasoconstriction.[5][6]

gollark: This is not a very good application.

gollark: ddg! site:pastebin.com "PotatOS"

gollark: ddg! PotatOS Tau, First Edition

gollark: But in a poorly programmed application ';-- or ');-- might work depending on what happens.

gollark: Obviously this won't actually do anything bad.

References

Waksman R, Gurbel P, Gaglia M (2014). Antiplatelet Therapy in Cardiovascular Disease. Hoboken, NJ: John Wiley & Sons. ISBN 9781118494028.
Hennerici MG, Bots ML, Ford I, Laurent S, Touboul PJ (April 2010). "Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial". Cardiovascular Drugs and Therapy. 24 (2): 175–80. doi:10.1007/s10557-010-6231-2. PMC 2887499. PMID 20490906.
Hennerici M, Binder J, Szabo K, Kern R (2012). Stroke. Oxford, UK: Oxford University Press. p. 155. ISBN 9780199582808.
Acton A (2012). Advances in Prostaglandins E Research and Application. Atlanta, GA: Scholarly Editions. p. 8. ISBN 9781481640084.CS1 maint: date and year (link)
Spreitzer H (January 29, 2007). "Neue Wirkstoffe - Terutroban". Österreichische Apothekerzeitung (in German) (3/2007): 116.
Sorbera LA, Serradell, N, Bolos, J, Bayes, M (2006). "Terutroban sodium". Drugs of the Future. 31 (10): 867–873. doi:10.1358/dof.2006.031.10.1038241.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Waksman R, Gurbel P, Gaglia M (2014). Antiplatelet Therapy in Cardiovascular Disease. Hoboken, NJ: John Wiley & Sons. ISBN 9781118494028.

[2] Hennerici MG, Bots ML, Ford I, Laurent S, Touboul PJ (April 2010). "Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial". Cardiovascular Drugs and Therapy. 24 (2): 175–80. doi:10.1007/s10557-010-6231-2. PMC 2887499. PMID 20490906.

[3] Hennerici M, Binder J, Szabo K, Kern R (2012). Stroke. Oxford, UK: Oxford University Press. p. 155. ISBN 9780199582808.

[4] Acton A (2012). Advances in Prostaglandins E Research and Application. Atlanta, GA: Scholarly Editions. p. 8. ISBN 9781481640084.CS1 maint: date and year (link)

[5] Spreitzer H (January 29, 2007). "Neue Wirkstoffe - Terutroban". Österreichische Apothekerzeitung (in German) (3/2007): 116.

[6] Sorbera LA, Serradell, N, Bolos, J, Bayes, M (2006). "Terutroban sodium". Drugs of the Future. 31 (10): 867–873. doi:10.1358/dof.2006.031.10.1038241.